BridgeBio's acoramidis cuts risk of first heart failure event by 45% versus placebo in trial
BBIO•BridgeBio Pharma said acoramidis cut the risk of a first heart failure event by 45% versus placebo in a trial. The company also reported benefits emerging within the first month and lower heart failure mortality through 54 months with continuous treatment.
1. Trial findings
BridgeBio Pharma said Phase 3 ATTRibute-CM findings showed fewer heart failure events with acoramidis versus placebo, with benefits emerging within the first month. Continuous treatment was associated with lower heart failure mortality through 54 months compared with delayed initiation.
2. Additional analyses
Kidney analyses found no clinically meaningful safety changes accompanying an early kidney-function dip, and function remained stable in participants with advanced kidney disease. The findings were presented at the 2026 American Heart Association Scientific Sessions and International Symposium on Amyloidosis.




